Patrick Campbell

FDA approved addition of OS to labeling based on results of the ADMIRAL trial.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain in Crohn's disease.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses a post hoc analysis of biomarkers and clinical outcomes in patients with ulcerative colitis receving etrasimod.

Investigators found that patients receiving cariprazine showed significant improvement in cognitive symptoms compared to patients receiving aripiprazole or placebo therapy.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

Preston Klassen, MD, head of research and development at Arena Pharamaceuticals, discusses mucosal healing and histologic remission in patients with ulcerative colitis receiving etrasimod.

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

An analysis of more than 62,000,000 found that prevalence rates of nonalcoholic fatty liver disease were 3 times higher in patients with Crohn's disease.

Investigators presented information on the 9-month interim results of the ABX464-102 phase 2a examining efficacy in UC patients at DDW 2019.

FDA announced approval of Sorilux Foam, which had previous approval for adults, for adolescents between the ages of 12 and 17.

David Kingdon, MD, FRCPsych, professor of mental health care delivery at the University of Southampton, sat down with MD Magazine at APA 2019 to discuss recent advances in psychosis.

Investigators from Baylor College of Medicine found that dawn to sunset fasting may be a new treatment approach for obesity, metabolic syndrome and NAFLD.

Study from DDW 2019 found that rates of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis was more than double in patients with UC.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

A study presented at DDW 2019 found that endoscopic retrieval may help prevent further gastric damage from button battery ingestion.

FDA approved midazolam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.

Study presented at DDW 2019 found that walking and resistance training was associated with a lower risk of cirrhosis-related death.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

A recent study found that recreational cannabis legalization can lead to increase in car accidents and injuries, but decreases in chronic pain admissions.

A recent study from the Mayo Clinic found that tramadol carries a risk of long-term use similar to that of oxycodone and hydrocodone.

Machine Learning algorithm analyzes 85 individual variables to determine a person's risk of having a heart attack or death with more than 90% accuracy.

Zebra Medical Vision received clearance for HealthPNX, an AI-based chest X-ray triage product.